[Stage I malignant melanoma of the skin. Prognostic value of thickness and level (author's transl)]. 1981

A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot

In a retrospective study of 95 patients seen between 1950 and 1978, the outcome of malignant melanoma levels III, IV and V of Clark's classification was reviewed. Patients with lentigo malignant melanoma were excluded. The overall survival rate was 63% at 5 years and 48% at 10 years. For the whole population of patients significant differences in survival rate were associated with level (p = 0,00002), thickness (less than 2 mm or greater than or equal to 2 mm; p less than 0.0,0001) and histological type (p = 0,02). The significance of prognostic variables taken separately was calculated by the Breslow method and was found to be: p = 0,0005 for thickness, p = 0,0009 for patient's age and p = 0,02 for histological type. In analysis with two variables, including level, thickness was the variable that added most to the information on prognosis supplied by level. For the population of patients with melanoma levels III and IV significant differences in survival rate were associated with thickness (less than 2 mm or greater than or equal to 2 mm; p less than 0,001), though not with level. When the variables were studied separately, thickness and patient's age were significant (p = 0,02 and p = 0,03 respectively). Analysis with two variables, including thickness, showed that age was the variable that added most to the information on prognosis supplied by thickness.

UI MeSH Term Description Entries
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age

Related Publications

A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
January 1975, Radiobiologia, radiotherapia,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
December 1978, Annales de dermatologie et de venereologie,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
September 1986, Analytical and quantitative cytology and histology,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
January 1983, Journal of clinical pathology,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
November 1976, Langenbecks Archiv fur Chirurgie,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
January 1998, Oncology reports,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
October 1989, Cancer,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
June 1973, Klinische Monatsblatter fur Augenheilkunde,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
June 1976, Wiener klinische Wochenschrift,
A Palangié, and F Lassau, and T Moreau, and G Noury-Duperrat, and F Cottenot
January 1972, Nowotwory,
Copied contents to your clipboard!